Merck & Co. Inc. managers escaped allegations that they hurt the pharmaceutical giant by misleading investors over traction ...

Merck stock reversed higher Thursday, though the company reported another quarter of light sales for its HPV vaccine, Gardasil.

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of $15.31 billion and $2.14, respectively.

While HHS Secretary Kennedy frets over food dye in Froot Loops, his 2023 attack on Gardasil — a vaccine proven to prevent ...

Merck MRK reported its first-quarter 2025 results last week, beating estimates for both earnings and sales. Adjusted earnings ...

Find insight on Merck, Sanofi and more in the latest Market Talks covering the Health Care sector.

Merck on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, reflecting a January decision to pause shipments of its Gardasil vaccine to China ...

A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus (HPV) vaccines Gardasil and Gardasil 9, marking a continued setback for the company’s ...

Market volatility has led to compelling dividend opportunities, and Merck and Schlumberger offer great value at low PE ratios. Read more on MRK and SLB stocks here.

The drugmaker is still dealing with the fallout over its HPV vaccine Gardasil in China, where a drop in demand forced it to halt shipments and rescind its previous forecast of $11 billion in ...

Why it matters: Investors have been particularly concerned about demand for HPV vaccine Gardasil in China, with uncertainty around pharmaceutical tariffs also weighing on shares. Gardasil's 41% ($ ...

A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus (HPV) vaccines Gardasil and Gardasil 9, marking a continued setback for the company’s ...